Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis

BACKGROUND AND OBJECTIVES: The principle defect in dense deposit disease and C3 glomerulonephritis is hyperactivity of the alternative complement pathway. Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, may prove beneficial. DESIGN, SETTING, PA...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bomback, Andrew S., Smith, Richard J., Barile, Gaetano R., Zhang, Yuzhou, Heher, Eliot C., Herlitz, Leal, Stokes, M. Barry, Markowitz, Glen S., D’Agati, Vivette D., Canetta, Pietro A., Radhakrishnan, Jai, Appel, Gerald B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Nephrology 2012
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3338285/
https://ncbi.nlm.nih.gov/pubmed/22403278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.12901211
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller